The remarkable success of the mRNA vaccines against Covid-19 has spurred the scientists at BioNTech to develop such a vaccine for malaria, a killer disease affecting much of Africa predominantly. The continent accounted for 94 percent of the 229 million cases of malaria and 409,000 malaria deaths in 2019, according to the WHO. The project also aims to build the vaccine manufacturing capacity on the continent. This novel technology makes it relatively easy and quick to produce vaccines, though it is still too early to predict similar success rates for the malaria vaccine. The fact that the project is supported by the WHO, the European Commission and the Bill and Melinda Gates Foundation gives reason for hope.

Read Full Story


More: